JP2016512832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512832A5 JP2016512832A5 JP2016501584A JP2016501584A JP2016512832A5 JP 2016512832 A5 JP2016512832 A5 JP 2016512832A5 JP 2016501584 A JP2016501584 A JP 2016501584A JP 2016501584 A JP2016501584 A JP 2016501584A JP 2016512832 A5 JP2016512832 A5 JP 2016512832A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- drug conjugate
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims description 70
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 70
- 239000003814 drug Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- -1 2,5-dioxopyrrolidin-1-yl Chemical group 0.000 claims description 6
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 claims description 4
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 4
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 4
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 4
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940121819 ATPase inhibitor Drugs 0.000 claims description 2
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 2
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 claims description 2
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 claims description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 2
- 239000012624 DNA alkylating agent Substances 0.000 claims description 2
- 229940126161 DNA alkylating agent Drugs 0.000 claims description 2
- 239000012623 DNA damaging agent Substances 0.000 claims description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 2
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims description 2
- 102100029095 Exportin-1 Human genes 0.000 claims description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 2
- 102100027670 Islet amyloid polypeptide Human genes 0.000 claims description 2
- 229940124179 Kinesin inhibitor Drugs 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 229940119336 Microtubule stabilizer Drugs 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 2
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims description 2
- 101150094313 XPO1 gene Proteins 0.000 claims description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108700002148 exportin 1 Proteins 0.000 claims description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000000138 intercalating agent Substances 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- 210000003470 mitochondria Anatomy 0.000 claims description 2
- 230000025308 nuclear transport Effects 0.000 claims description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 2
- 238000006276 transfer reaction Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000000516 mast-cell leukemia Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793641P | 2013-03-15 | 2013-03-15 | |
| US61/793,641 | 2013-03-15 | ||
| PCT/US2014/024597 WO2014150937A1 (en) | 2013-03-15 | 2014-03-12 | Antibody drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018049209A Division JP6578400B2 (ja) | 2013-03-15 | 2018-03-16 | 抗体薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512832A JP2016512832A (ja) | 2016-05-09 |
| JP2016512832A5 true JP2016512832A5 (enExample) | 2017-04-13 |
| JP6333943B2 JP6333943B2 (ja) | 2018-05-30 |
Family
ID=50721874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501584A Expired - Fee Related JP6333943B2 (ja) | 2013-03-15 | 2014-03-12 | 抗体薬物コンジュゲート |
| JP2018049209A Expired - Fee Related JP6578400B2 (ja) | 2013-03-15 | 2018-03-16 | 抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018049209A Expired - Fee Related JP6578400B2 (ja) | 2013-03-15 | 2018-03-16 | 抗体薬物コンジュゲート |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US9498543B2 (enExample) |
| EP (2) | EP3514178A1 (enExample) |
| JP (2) | JP6333943B2 (enExample) |
| KR (1) | KR20150131173A (enExample) |
| CN (1) | CN105007950B (enExample) |
| AP (1) | AP2015008656A0 (enExample) |
| AR (1) | AR095666A1 (enExample) |
| AU (1) | AU2014235474B2 (enExample) |
| BR (1) | BR112015021134A2 (enExample) |
| CA (1) | CA2903772A1 (enExample) |
| CL (1) | CL2015002246A1 (enExample) |
| CR (1) | CR20150488A (enExample) |
| CU (1) | CU20150128A7 (enExample) |
| EA (1) | EA035253B1 (enExample) |
| ES (1) | ES2701051T3 (enExample) |
| IL (1) | IL241277A0 (enExample) |
| MA (1) | MA38396B1 (enExample) |
| MX (1) | MX366978B (enExample) |
| NZ (1) | NZ710929A (enExample) |
| PH (1) | PH12015501902A1 (enExample) |
| SG (1) | SG11201506395RA (enExample) |
| TN (1) | TN2015000396A1 (enExample) |
| TW (1) | TW201446806A (enExample) |
| UY (1) | UY35490A (enExample) |
| WO (1) | WO2014150937A1 (enExample) |
| ZA (1) | ZA201505656B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6058650B2 (ja) | 2011-06-17 | 2017-01-11 | インビスタ テクノロジーズ エス．アー．エール．エル． | 廃棄流中のモノマー含有量を増大させるためのヒドロラーゼの使用 |
| BR112015021134A2 (pt) * | 2013-03-15 | 2017-10-10 | Novartis Ag | conjugados de fármaco e anticorpo |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| TN2016000577A1 (en) | 2014-08-12 | 2018-04-04 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
| EP3268038B1 (en) * | 2015-03-09 | 2021-05-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to flt3 proteins |
| WO2017060322A2 (en) * | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| MA44334A (fr) * | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| US11052111B2 (en) * | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| KR20190038537A (ko) | 2016-06-17 | 2019-04-08 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
| CN107913410B (zh) * | 2016-10-08 | 2021-02-02 | 浙江大学 | 两亲性共聚物-美登素类共价偶联药物、制备方法及应用 |
| JOP20190155A1 (ar) * | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم |
| KR102725761B1 (ko) | 2017-01-20 | 2024-11-04 | 하이델베르크 파마 리서치 게엠베하 | Cd137+ 세포의 고갈을 위한 조성물 및 방법 |
| JOP20190187A1 (ar) * | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| CN108456213B (zh) * | 2017-02-22 | 2021-01-15 | 浙江九洲药业股份有限公司 | 一种3-氟-4-羟基环己烷羧酸酯的制备方法 |
| CN110430901B (zh) | 2017-03-24 | 2024-08-16 | 西雅图基因公司 | 制备葡糖苷酸药物-接头及其中间体的方法 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| TW201945026A (zh) * | 2018-01-29 | 2019-12-01 | 美商希拉諾斯醫療公司 | 結合erfe之抗體及使用方法 |
| GB201802201D0 (en) | 2018-02-09 | 2018-03-28 | Ultrahuman Five Ltd | Binding agents |
| US20210009711A1 (en) * | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| US20210231651A1 (en) * | 2018-04-30 | 2021-07-29 | Genalyte, Inc. | Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics |
| TW202014209A (zh) * | 2018-06-20 | 2020-04-16 | 瑞士商諾華公司 | 用於消融造血幹細胞之抗體藥物軛合物 |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| KR102716514B1 (ko) * | 2018-10-10 | 2024-10-15 | 주식회사 노벨티노빌리티 | 신규 항-c-KIT 항체 |
| UA128431C2 (uk) | 2018-11-26 | 2024-07-10 | Форті Севен, Інк. | ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| SG11202108955QA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Antibody molecules that bind to nkp30 and uses thereof |
| US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| MX2021012961A (es) * | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| JP2022529727A (ja) * | 2019-04-24 | 2022-06-23 | マジェンタ セラピューティクス インコーポレイテッド | Ａｎｔｉ－ｃｄ１１７ とその使用 |
| CN114728076A (zh) * | 2019-05-20 | 2022-07-08 | 诺华股份有限公司 | Mcl-1抑制剂抗体-药物缀合物及使用方法 |
| CN111620927B (zh) * | 2019-05-20 | 2022-11-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物中间体的一锅法制备工艺 |
| CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
| CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN115894606A (zh) | 2019-11-04 | 2023-04-04 | 锐新医药公司 | Ras抑制剂 |
| KR20220100903A (ko) | 2019-11-08 | 2022-07-18 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
| KR102772859B1 (ko) * | 2019-11-25 | 2025-02-27 | 주식회사 노벨티노빌리티 | c-kit에 대한 항체 및 이의 용도 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| EP4359436A1 (en) | 2021-06-22 | 2024-05-01 | Novartis AG | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
| KR102544135B1 (ko) * | 2022-01-26 | 2023-06-19 | 주식회사 노벨티노빌리티 | c-Kit을 표적으로 하는 면역접합체 |
| CN119072334A (zh) * | 2022-02-17 | 2024-12-03 | 新奇贵族公司 | 抗体-药物偶联物 |
| KR20250007588A (ko) | 2022-04-26 | 2025-01-14 | 노파르티스 아게 | Il-13 및 il-18을 표적화하는 다중특이적 항체 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025068957A1 (en) | 2023-09-29 | 2025-04-03 | Novartis Ag | Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN120427902B (zh) * | 2025-07-04 | 2025-09-12 | 杭州华得森生物技术有限公司 | 链霉亲和素偶联抗体捕获ctc检测试剂盒 |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
| US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| ES2118820T3 (es) | 1991-04-05 | 1998-10-01 | Univ Washington | Anticuerpos monoclonales para receptores de factores de celulas pluripotentes. |
| ATE221379T1 (de) | 1991-05-01 | 2002-08-15 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
| US5545533A (en) | 1991-05-25 | 1996-08-13 | Boehringer Mannheim Gmbh | Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| AU4755696A (en) | 1995-01-05 | 1996-07-24 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Surface-modified nanoparticles and method of making and using same |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| DE19600589C1 (de) | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antikörper A3C6E2 |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
| PT1144607E (pt) | 1999-07-20 | 2009-04-22 | Morphosys Ag | Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto |
| DK1242401T3 (da) | 1999-11-24 | 2007-05-07 | Immunogen Inc | Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf |
| PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
| EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
| US6411163B1 (en) | 2000-08-14 | 2002-06-25 | Intersil Americas Inc. | Transconductance amplifier circuit |
| CA2445898A1 (en) * | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
| ES2485841T3 (es) | 2002-02-01 | 2014-08-14 | Ariad Pharmaceuticals, Inc | Compuestos que contienen fósforo y usos de los mismos |
| US20050069551A1 (en) | 2002-03-08 | 2005-03-31 | Emory University | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis |
| JP4575667B2 (ja) | 2002-03-08 | 2010-11-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬として有用な大環状化合物 |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| ES2318167T3 (es) | 2002-07-15 | 2009-05-01 | The Trustees Of Princeton University | Compuestos de union a iap. |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| NO347360B1 (no) * | 2003-10-10 | 2023-09-25 | Immunogen Inc | Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse. |
| US7932382B2 (en) | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| CN1933847A (zh) | 2004-01-16 | 2007-03-21 | 密歇根大学董事会 | Smac肽模拟物及其应用 |
| CA2558615C (en) | 2004-03-23 | 2013-10-29 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| EP2253614B1 (en) | 2004-04-07 | 2012-09-19 | Novartis AG | Inhibitors of IAP |
| MXPA06014969A (es) | 2004-07-02 | 2007-02-08 | Genentech Inc | Inhibidores de iap. |
| WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| CA2573644A1 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| EP1773766B1 (en) | 2004-07-15 | 2014-04-02 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
| ATE477254T1 (de) | 2004-12-20 | 2010-08-15 | Genentech Inc | Pyrrolidine als inhibitoren von iap |
| AU2006213662B2 (en) | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| US20110166319A1 (en) | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1912636B1 (en) | 2005-07-21 | 2014-06-25 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| CN101267841B (zh) | 2005-08-24 | 2012-10-10 | 免疫原公司 | 制备美登木素生物碱抗体缀合物的方法 |
| WO2007030642A2 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| CN101687787A (zh) | 2007-04-30 | 2010-03-31 | 健泰科生物技术公司 | Iap的抑制剂 |
| CN103694351A (zh) * | 2007-06-05 | 2014-04-02 | 耶鲁大学 | 受体酪氨酸激酶抑制剂及其使用方法 |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| US8236319B2 (en) | 2008-04-30 | 2012-08-07 | Immunogen, Inc. | Cross-linkers and their uses |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| US20130011406A1 (en) | 2010-03-26 | 2013-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| EP3763740A1 (en) * | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| MX339927B (es) | 2011-03-29 | 2016-06-16 | Immunogen Inc | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. |
| MX2013011201A (es) | 2011-03-29 | 2013-12-16 | Immunogen Inc | Proceso para la elaboracion de conjugados de mejor homogeneidad. |
| AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| CN104812775B (zh) | 2012-07-25 | 2019-05-03 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| BR112015021134A2 (pt) * | 2013-03-15 | 2017-10-10 | Novartis Ag | conjugados de fármaco e anticorpo |
| US11605302B2 (en) | 2020-11-10 | 2023-03-14 | Rockwell Collins, Inc. | Time-critical obstacle avoidance path planning in uncertain environments |
-
2014
- 2014-03-12 BR BR112015021134A patent/BR112015021134A2/pt not_active Application Discontinuation
- 2014-03-12 NZ NZ710929A patent/NZ710929A/en not_active IP Right Cessation
- 2014-03-12 EP EP18188339.8A patent/EP3514178A1/en not_active Withdrawn
- 2014-03-12 EP EP14723915.6A patent/EP2968590B1/en active Active
- 2014-03-12 KR KR1020157028519A patent/KR20150131173A/ko not_active Ceased
- 2014-03-12 EA EA201591801A patent/EA035253B1/ru not_active IP Right Cessation
- 2014-03-12 US US14/205,915 patent/US9498543B2/en not_active Expired - Fee Related
- 2014-03-12 WO PCT/US2014/024597 patent/WO2014150937A1/en not_active Ceased
- 2014-03-12 US US14/774,512 patent/US9789203B2/en active Active
- 2014-03-12 CN CN201480013720.XA patent/CN105007950B/zh not_active Expired - Fee Related
- 2014-03-12 CA CA2903772A patent/CA2903772A1/en not_active Abandoned
- 2014-03-12 MX MX2015013203A patent/MX366978B/es active IP Right Grant
- 2014-03-12 MA MA38396A patent/MA38396B1/fr unknown
- 2014-03-12 AU AU2014235474A patent/AU2014235474B2/en not_active Ceased
- 2014-03-12 AP AP2015008656A patent/AP2015008656A0/xx unknown
- 2014-03-12 ES ES14723915T patent/ES2701051T3/es active Active
- 2014-03-12 SG SG11201506395RA patent/SG11201506395RA/en unknown
- 2014-03-12 JP JP2016501584A patent/JP6333943B2/ja not_active Expired - Fee Related
- 2014-03-14 TW TW103109292A patent/TW201446806A/zh unknown
- 2014-03-17 UY UY0001035490A patent/UY35490A/es not_active Application Discontinuation
- 2014-03-18 AR ARP140101272A patent/AR095666A1/es unknown
-
2015
- 2015-05-20 US US14/717,578 patent/US20150320880A1/en not_active Abandoned
- 2015-08-05 ZA ZA2015/05656A patent/ZA201505656B/en unknown
- 2015-08-12 CL CL2015002246A patent/CL2015002246A1/es unknown
- 2015-08-27 PH PH12015501902A patent/PH12015501902A1/en unknown
- 2015-09-04 TN TN2015000396A patent/TN2015000396A1/en unknown
- 2015-09-07 IL IL241277A patent/IL241277A0/en unknown
- 2015-09-14 CR CR20150488A patent/CR20150488A/es unknown
- 2015-09-15 CU CUP2015000128A patent/CU20150128A7/es unknown
-
2016
- 2016-10-03 US US15/284,444 patent/US10117953B2/en not_active Expired - Fee Related
-
2017
- 2017-08-30 US US15/690,737 patent/US20180125996A1/en not_active Abandoned
-
2018
- 2018-03-16 JP JP2018049209A patent/JP6578400B2/ja not_active Expired - Fee Related
-
2019
- 2019-12-09 US US16/708,196 patent/US20200129632A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512832A5 (enExample) | ||
| JP2016518332A5 (enExample) | ||
| JP2018501781A5 (enExample) | ||
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| TWI794230B (zh) | 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法 | |
| JP7401126B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
| EP3429693B1 (en) | Napi2b-targeted antibody-drug conjugates and methods of use thereof | |
| JP5925875B2 (ja) | 抗体−薬剤コンジュゲート | |
| JP2021516960A5 (enExample) | ||
| JP2015523961A5 (enExample) | ||
| CN110869393A (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
| RU2018134331A (ru) | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения | |
| CN111587124A (zh) | Ror1抗体免疫缀合物 | |
| NZ762376A (en) | Transglutaminase conjugation method and linker | |
| SI2582728T1 (en) | Human Antibodies Conjugates against a Tissue Factor | |
| EP4378958A3 (en) | High-affinity anti-mertk antibodies and uses thereof | |
| TW201116300A (en) | DR5 Ligand Drug Conjugates | |
| JP2015528818A5 (enExample) | ||
| WO2005117986A3 (en) | Antibody drug conjugates and methods | |
| JP2016528882A5 (enExample) | ||
| IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
| EP3638306A1 (en) | Antibody-drug conjugates containing anti-globo h antibodies and uses thereof | |
| WO2024145398A1 (en) | Antibody drug conjugates | |
| JP2016511257A (ja) | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 |